Authors
Juan Carlos Montero, Verónica Fraile Rivero, María José Doyague, Mar Abad, Atanasio Pandiella
Published in
Signal transduction and targeted therapy. Volume 11. Issue 1. Jun 26, 2026. Epub Jun 26, 2026.
Abstract
Ovarian cancer remains a challenging malignancy with high recurrence rates and limited long-term therapeutic success. Antibody-drug conjugates (ADCs) represent a promising therapeutic class capable of delivering potent cytotoxic agents selectively to tumor cells. In this study, we investigated the potential of CD98hc, a transmembrane glycoprotein involved in amino acid transport and cell signaling, as a novel target for ADCs in ovarian cancer. Western blotting and immunohistochemistry analyses revealed higher CD98hc expression in ovarian tumor tissues compared to normal ovarian tissue. Flow cytometry and immunofluorescence studies confirmed that an antibody against the extracellular domain of CD98hc bound cell surface CD98hc and internalized to lysosomes. Using this antibody, we generated ADCs containing the payloads DM1, MMAF, or DXd. Among these, the anti-CD98hc-MMAF construct showed superior cytotoxicity in ovarian cancer cell lines, with IC50 values in the picomolar range. The anti-CD98hc-MMAF ADC also effectively inhibited the proliferation of tumor cells cultured from ascitic fluids of ovarian cancer patients. Mechanistic studies showed that anti-CD98hc-MMAF induced G2/M cell cycle arrest, mitotic spindle disruption, and apoptotic cell death. In vivo, treatment with a humanized anti-CD98hc-MMAF ADC significantly suppressed tumor growth and metastatic implantation in xenografted mice, without apparent toxicity. These findings validate CD98hc as a promising target for ADC therapy in ovarian cancer and support the clinical development of anti-CD98hc-MMAF.
PMID:
42350421
Bibliographic data and abstract were imported from PubMed on 26 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0